Sentence examples for serious bleeding compared from inspiring English sources

Serious bleeding rates were consistent with those observed in previous studies throughout the 6-day treatment period, and prophylactic heparin did not increase the risk for serious bleeding compared with placebo (2.3%and2.5%5%, respectively), including CNS bleeding (0.3% in both arms).

Also, people in the celecoxib group were less likely to have serious gastrointestinal bleeding compared with those in the other two groups.

The main common findings of these surveys were a higher overall mortality and incidence of serious bleeding events compared with PROWESS [ 16, 17].

The pivotal phase 3 placebo-controlled clinical trial PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) demonstrated a 19.4% relative risk reduction in 28-day mortality (6.1% absolute risk reduction) with an increased risk (3.5% versus 2.0%) of serious bleeding events compared with placebo [ 4].

The pivotal phase 3 placebo-controlled Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) clinical trial demonstrated a 19.4% relative risk reduction in 28-day mortality (6.1% absolute risk reduction) with an increased risk (3.5% versus 2.0%) of serious bleeding events compared with placebo.

Administration of DrotAA was associated with an increased risk for serious bleeding during the infusion period in both the overall PROWESS patients (P = 0.024) and the surgical cohort (P = 0.006); however, the surgical patients did not demonstrate excessive risk of bleeding compared with nonsurgical patients who received DrotAA.

Moreover, there are safety concerns, including increased incidence of serious bleeding after DAA compared to placebo (5.6% DAA; 2.0% placebo, P < 0.001) [9].

Prophylactic heparin did not increase the risk for serious bleeding for DrotAA compared with placebo (3.9% versus 5.2%, respectively), including CNS bleeding (1.0% versus 0.7%, respectively).

As was anticipated, administration of drotrecogin alfa (activated) was associated with an increased incidence of serious bleeding events as compared with placebo (3.5% versus 2.0%; P = 0.06).

Moreover, there are safety concerns, including increased incidence of serious bleeding after DAA compared to placebo (5.6% DAA; 2.0% placebo, P < 0.001) [ 9].

Patients with a platelet count below 50,000/mm, either at entry or during the first 5 days of study, exhibited an increased incidence of serious bleeding events as compared with the rest of the population, and this was observed in both placebo and drotrecogin alfa (activated) treated patients [ 11].